Lung cancer (non-small cell)
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Who can joinAdults
Age18+ years
Kind of studyPhase 3: compared with usual treatment
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Where to go
8 hospitals in India taking patients for this trial.
Manipal HospitalsBengaluru, KarnatakaDirections ↗
Regional Cancer Centre - ThiruvananthapuramThiruvananthapuram, KeralaDirections ↗
Mumbai Oncocare Centre Vile ParleMumbai, MaharashtraDirections ↗
Tata Memorial HospitalMumbai, MaharashtraDirections ↗
All India Institute of Medical SciencesNew Delhi, National Capital Territory of DelhiDirections ↗
Rajiv Gandhi Cancer Institute And Research CentreNew Delhi, National Capital Territory of DelhiDirections ↗
Yashoda HospitalSecunderabad, TelanganaDirections ↗
Narayana Superspecialty HospitalHowrah, West BengalDirections ↗
Registry summary (technical)
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%
Sponsor: Bristol-Myers Squibb
NCT06561386 on ClinicalTrials.gov
Last updated on the registry 23 Sep 2026 · read by us 20 Oct 2026